Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

292 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. Among authors: yuen e. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials.
Liu E, Schmidt ME, Margolin R, Sperling R, Koeppe R, Mason NS, Klunk WE, Mathis CA, Salloway S, Fox NC, Hill DL, Les AS, Collins P, Gregg KM, Di J, Lu Y, Tudor IC, Wyman BT, Booth K, Broome S, Yuen E, Grundman M, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Liu E, et al. Among authors: yuen e. Neurology. 2015 Aug 25;85(8):692-700. doi: 10.1212/WNL.0000000000001877. Epub 2015 Jul 24. Neurology. 2015. PMID: 26208959 Free PMC article. Clinical Trial.
Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease.
Novak G, Fox N, Clegg S, Nielsen C, Einstein S, Lu Y, Tudor IC, Gregg K, Di J, Collins P, Wyman BT, Yuen E, Grundman M, Brashear HR, Liu E. Novak G, et al. Among authors: yuen e. J Alzheimers Dis. 2016;49(4):1123-34. doi: 10.3233/JAD-150448. J Alzheimers Dis. 2016. PMID: 26639957 Clinical Trial.
2012: A watershed year for Alzheimer's disease research.
Grundman M, Dibernardo A, Raghavan N, Krams M, Yuen E. Grundman M, et al. Among authors: yuen e. J Nutr Health Aging. 2013 Jan;17(1):51-3. doi: 10.1007/s12603-013-0002-2. J Nutr Health Aging. 2013. PMID: 23299380 Free article.
A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment.
Thal LJ, Ferris SH, Kirby L, Block GA, Lines CR, Yuen E, Assaid C, Nessly ML, Norman BA, Baranak CC, Reines SA; Rofecoxib Protocol 078 study group. Thal LJ, et al. Among authors: yuen e. Neuropsychopharmacology. 2005 Jun;30(6):1204-15. doi: 10.1038/sj.npp.1300690. Neuropsychopharmacology. 2005. PMID: 15742005 Clinical Trial.
Randomized, placebo-controlled trial of rofecoxib in the acute treatment of migraine.
Silberstein S, Tepper S, Brandes J, Diamond M, Goldstein J, Winner P, Venkatraman S, Vrijens F, Malbecq W, Lines C, Visser WH, Reines S, Yuen E. Silberstein S, et al. Among authors: yuen e. Neurology. 2004 May 11;62(9):1552-7. doi: 10.1212/01.wnl.0000123260.61631.c4. Neurology. 2004. PMID: 15136680 Clinical Trial.
Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis.
Miller RG, Moore DH 2nd, Gelinas DF, Dronsky V, Mendoza M, Barohn RJ, Bryan W, Ravits J, Yuen E, Neville H, Ringel S, Bromberg M, Petajan J, Amato AA, Jackson C, Johnson W, Mandler R, Bosch P, Smith B, Graves M, Ross M, Sorenson EJ, Kelkar P, Parry G, Olney R; Western ALS Study Group. Miller RG, et al. Among authors: yuen e. Neurology. 2001 Apr 10;56(7):843-8. doi: 10.1212/wnl.56.7.843. Neurology. 2001. PMID: 11294919 Clinical Trial.
292 results